as 06-05-2025 4:00pm EST
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
Founded: | 2015 | Country: | United States |
Employees: | N/A | City: | NEW HAVEN |
Market Cap: | 456.2M | IPO Year: | 2018 |
Target Price: | $20.53 | AVG Volume (30 days): | 2.2M |
Analyst Decision: | Buy | Number of Analysts: | 21 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.65 | EPS Growth: | N/A |
52 Week Low/High: | $5.90 - $34.11 | Next Earning Date: | 07-29-2025 |
Revenue: | $426,900,000 | Revenue Growth: | 498.74% |
Revenue Growth (this year): | 2.83% | Revenue Growth (next year): | -46.51% |
Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
Berkowitz Noah | ARVN | Chief Medical Officer | Mar 18 '25 | Sell | $8.59 | 8,658 | $74,372.22 | 110,023 |
ARVN Breaking Stock News: Dive into ARVN Ticker-Specific Updates for Smart Investing
GlobeNewswire
10 hours ago
MT Newswires
3 days ago
GlobeNewswire
5 days ago
BioPharma Dive
6 days ago
Zacks
6 days ago
GlobeNewswire
6 days ago
Clinical Trials Arena
7 days ago
MT Newswires
21 days ago
The information presented on this page, "ARVN Arvinas Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.